Rate My Professor Sally Ward

Professor Ward's pioneering research centers on the neonatal Fc receptor (FcRn), which she identified as key to regulating IgG antibody levels and persistence, leading to therapeutic strategies for extending antibody half-lives or depleting pathogenic antibodies in autoimmunity, cancer immunotherapy, and infectious diseases. Her work includes mechanistic studies of FcRn function and development of Fc-engineered antibodies and FcRn antagonists. Key publications encompass 'Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli' (Nature, 1989), 'Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels' (Nature Biotechnology, 2005), 'Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy' (Nature Biotechnology, 2019), 'FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma' (Nature Communications, 2025), and 'Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin' (JCI Insight, 2024). These contributions have profoundly influenced biopharmaceutical development, including first-in-class FcRn inhibitors like efgartigimod for myasthenia gravis and pemphigus vulgaris. Honors include the Established Investigator Award (American Heart Association, 1997), Royal Society Wolfson Research Merit Award (2018-2023), Fellow of the Royal Society (2022), and International Society of Molecular Recognition Award in Affinity Technology (2025). She served as President of The Antibody Society (2022-2023), Vice-President (2020-2021), and holds positions on scientific advisory boards and editorial committees.